Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more
Aurobindo Pharma Limited (AUROPHARMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.082x
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has a cash flow conversion efficiency ratio of 0.082x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹28.85 Billion) by net assets (₹350.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aurobindo Pharma Limited - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Aurobindo Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aurobindo Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aurobindo Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mobile World Investment Corp
VN:MWG
|
-0.018x |
|
PriceSmart Inc
NASDAQ:PSMT
|
0.055x |
|
Hua Hong Semiconductor Limited
PINK:HHUSF
|
0.024x |
|
Broadex Technologies Co Ltd
SHE:300548
|
0.067x |
|
Ampol Limited
F:CLZ
|
0.088x |
|
MDU Resources Group Inc
NYSE:MDU
|
0.008x |
|
Nordnet AB (publ)
LSE:0A6V
|
N/A |
|
Western Superconducting Tech Co Ltd
SHG:688122
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Aurobindo Pharma Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Aurobindo Pharma Limited from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹326.47 Billion | ₹39.25 Billion | 0.120x | +47.40% |
| 2024-03-31 | ₹298.51 Billion | ₹24.35 Billion | 0.082x | -8.25% |
| 2023-03-31 | ₹268.52 Billion | ₹23.87 Billion | 0.089x | -56.46% |
| 2022-03-31 | ₹245.74 Billion | ₹50.16 Billion | 0.204x | +34.47% |
| 2021-03-31 | ₹219.29 Billion | ₹33.29 Billion | 0.152x | -41.70% |
| 2020-03-31 | ₹168.25 Billion | ₹43.81 Billion | 0.260x | +119.12% |
| 2019-03-31 | ₹138.92 Billion | ₹16.51 Billion | 0.119x | -28.97% |
| 2018-03-31 | ₹116.82 Billion | ₹19.55 Billion | 0.167x | -52.16% |
| 2017-03-31 | ₹93.74 Billion | ₹32.79 Billion | 0.350x | +67.95% |
| 2016-03-31 | ₹68.18 Billion | ₹14.20 Billion | 0.208x | -12.75% |
| 2015-03-31 | ₹51.82 Billion | ₹12.37 Billion | 0.239x | +39.45% |
| 2014-03-31 | ₹37.76 Billion | ₹6.46 Billion | 0.171x | +63.26% |
| 2013-03-31 | ₹26.22 Billion | ₹2.75 Billion | 0.105x | -24.48% |
| 2012-03-31 | ₹23.50 Billion | ₹3.26 Billion | 0.139x | +1.45% |
| 2011-03-31 | ₹24.49 Billion | ₹3.35 Billion | 0.137x | -41.49% |
| 2010-03-31 | ₹18.33 Billion | ₹4.29 Billion | 0.234x | +113.93% |
| 2009-03-31 | ₹12.44 Billion | ₹1.36 Billion | 0.109x | -22.37% |
| 2008-03-31 | ₹11.27 Billion | ₹1.59 Billion | 0.141x | +571.59% |
| 2007-03-31 | ₹8.90 Billion | ₹186.50 Million | 0.021x | +289.34% |
| 2006-03-31 | ₹8.17 Billion | ₹-90.50 Million | -0.011x | -106.48% |
| 2005-03-31 | ₹7.14 Billion | ₹1.22 Billion | 0.171x | +522.70% |
| 2004-03-31 | ₹7.25 Billion | ₹198.90 Million | 0.027x | -- |